InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
无可用的信号评分。
Explore the complete record of transactions filed by Sands Capital Life Sciences Pulse Fund II, L.P.. Director active across 1 company, notably Inhibikase Therapeutics, Inc.. Cumulatively, 1 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €2.6m. History available since 21 November 2025. The latest transaction was disclosed on 21 November 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 条申报中的 1 条